Technical Analysis for IMCR - Immunocore Holdings plc

Grade Last Price % Change Price Change
F 35.83 -0.28% -0.10
IMCR closed down 0.28 percent on Monday, June 24, 2024, on 50 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -0.28%
New 52 Week Low Weakness -0.28%
Outside Day Range Expansion -0.28%
Wide Bands Range Expansion -0.28%
Oversold Stochastic Weakness -0.28%
New 52 Week Closing Low Bearish 2.02%
NR7 Range Contraction 2.02%

   Recent Intraday Alerts

Alert Time
Down 2 % about 15 hours ago
60 Minute Opening Range Breakdown about 16 hours ago
Down 1% about 18 hours ago
Up 1% about 18 hours ago
Rose Above Previous Day's High about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immunocore Holdings plc Description

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Infectious Diseases Autoimmune Disease Oncology Breast Cancer Virotherapy Immunotherapies Small Cell Lung Cancer Solid Tumor Cancers Oncolytics Biotech Treatment Of Autoimmune Disease Chronic Hepatitis B Virus Immunocore Pelareorep

Is IMCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 76.98
52 Week Low 35.025
Average Volume 865,408
200-Day Moving Average 57.15
50-Day Moving Average 50.47
20-Day Moving Average 41.36
10-Day Moving Average 38.00
Average True Range 1.98
RSI (14) 21.88
ADX 58.94
+DI 7.77
-DI 43.51
Chandelier Exit (Long, 3 ATRs) 45.56
Chandelier Exit (Short, 3 ATRs) 40.97
Upper Bollinger Bands 49.39
Lower Bollinger Band 33.33
Percent B (%b) 0.16
BandWidth 38.84
MACD Line -4.51
MACD Signal Line -4.34
MACD Histogram -0.1698
Fundamentals Value
Market Cap 1.77 Billion
Num Shares 49.4 Million
EPS -1.42
Price-to-Earnings (P/E) Ratio -25.23
Price-to-Sales 19.11
Price-to-Book 10.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.59
Resistance 3 (R3) 37.54 36.92 37.29
Resistance 2 (R2) 36.92 36.47 36.94 37.19
Resistance 1 (R1) 36.37 36.19 36.06 36.42 37.10
Pivot Point 35.75 35.75 35.59 35.77 35.75
Support 1 (S1) 35.20 35.30 34.89 35.25 34.56
Support 2 (S2) 34.58 35.02 34.60 34.47
Support 3 (S3) 34.03 34.58 34.37
Support 4 (S4) 34.08